First-generation H1 antagonist — bromine analog of chlorpheniramine. OTC component of multi-ingredient cold formulations. Same sedation + anticholinergic profile.
Half-Life & Elimination Curve (PO: 25h)
Plasma (PO)t½ Decay (25h)
0×t½0h100%(3.22 µg/L)
1×t½25h50%(1.61 µg/L)
2×t½50h25%(0.804 µg/L)
3×t½3.1d12.5%(0.402 µg/L)
4×t½4.2d6.3%(0.201 µg/L)
5×t½5.2d3.1%(0.1 µg/L)
Elimination t½25h (PO)
Rate Constant (ke)0.0277 h⁻¹
Time to Peak (Tmax)2.17h
Est. Peak (Cmax)3.22 µg/L
Clearance (CL)22.7 L/h
97% Washout (5×t½)5.2d
Dosing Guidelines
Oral (PO): Typical 4 mg (Range: 4–24 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 70% · Volume of Distribution (Vd): 820 L · Absorption (ka): 2 h⁻¹ (t½ka ≈ 21m) [PMID 6128358]